ImmunityBio, Inc.IBRXNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank69
3Y CAGR+47.6%
5Y CAGR-31.1%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+47.6%/yr
vs -26.1%/yr prior
5Y CAGR
-31.1%/yr
Recent acceleration
Acceleration
+73.7pp
Accelerating
Percentile
P69
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 7.89% |
| Q3 2025 | 27.34% |
| Q2 2025 | 28.61% |
| Q1 2025 | -119.14% |
| Q4 2024 | 30.99% |
| Q3 2024 | 36.29% |
| Q2 2024 | -0.34% |
| Q1 2024 | 42.54% |
| Q4 2023 | -144.18% |
| Q3 2023 | 30.68% |
| Q2 2023 | -18.51% |
| Q1 2023 | -7.51% |
| Q4 2022 | 2.45% |
| Q3 2022 | -17.29% |
| Q2 2022 | 8.01% |
| Q1 2022 | -12.67% |
| Q4 2021 | -4.14% |
| Q3 2021 | 0.75% |
| Q2 2021 | -10.90% |
| Q1 2021 | -147.77% |
| Q4 2020 | 51.02% |
| Q3 2020 | -27.54% |
| Q2 2020 | -38.88% |
| Q1 2020 | -66.27% |
| Q4 2019 | -42.92% |
| Q3 2019 | 6.57% |
| Q2 2019 | 6.73% |
| Q1 2019 | -3.14% |
| Q4 2018 | 26.63% |
| Q3 2018 | 14.77% |
| Q2 2018 | -0.77% |
| Q1 2018 | -12.38% |
| Q4 2017 | -2.16% |
| Q3 2017 | -2.20% |
| Q2 2017 | 4.34% |
| Q1 2017 | -1.14% |
| Q4 2016 | 24.01% |
| Q3 2016 | 6.18% |
| Q2 2016 | -10.92% |
| Q1 2016 | 60.10% |